[Market Focus] NextBioMedical Hits Record High on Hopes for Entry into U.S. Medical Device Market
NextBioMedical continues to show strong performance in the afternoon trading session.
As of 1:40 p.m. on November 27, shares of NextBioMedical were trading at 83,800 won, up 9.26% (7,100 won) from the previous day. During the session, the stock surged to as high as 89,600 won, setting a new 52-week high.
Investor sentiment was boosted by news that the company has completed the pre-submission process with the U.S. Food and Drug Administration (FDA) for its self-developed vascular embolization medical device, Nexphere. Previously, Nexphere had already secured certification from the Ministry of Food and Drug Safety (MFDS) in Korea and the European CE mark. The recent pre-submission consultation with the FDA is considered a significant step toward entering the U.S. market.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
According to the company, Nexphere is a vascular embolization medical device composed of a hydrophilic material containing gelatin. It is used to temporarily block blood flow to a targeted area by mixing it with a contrast agent and injecting it into the blood vessel through a catheter during embolization procedures.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.